



Annual General Meeting

13 November 2017



ANATARA
LIFESCIENCES

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anantara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.

Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.

Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.

Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.



Investment Highlights


- Anatarata is commercialising non-antibiotic oral products for gastrointestinal disease in animals and humans where there is a significant unmet need
- Company well funded with \$9.6m in bank
- Strong growth since IPO, with share price up 305% since listing
- Lead product, Detach[®] readying for launch, supported by:
 - Negotiations with leading animal health company, Zoetis Inc, for a worldwide development, distribution and marketing agreement
 - Direct efforts to prepare for Australian launch, including gathering market intelligence, acceptance testing and seeking regulatory approval
 - Commencement of human development program; establishment of a research laboratory in Melbourne
 - Extension of IP and growth in Anatarata's team and infrastructure, with several key appointments



Key Financial Details

ASX Code ANR	Market Capitalisation¹ \$78.1 million	Share Price¹ \$1.58
Current Cash² \$9.6 million	Ordinary Shares 49,413,236	Share Price up 305% since IPO

1. As at 9 November 2017
2. Appendix 4C - 30 September 2017



ANR Share Price Chart



Share price from IPO to 9 November 2017



Key Investor Message

The Anantara team is focussed on delivering commercial outcomes through application of the Company's technology in both the pork industry, and in human health. More than ever, the world is looking for safe and effective solutions to gut health.



Key FY17 Achievements

- Submission of dossier to the APVMA, seeking Detach[®] regulatory approval
- In negotiation with #1 global animal health company, Zoetis Inc, for a worldwide commercial agreement for Detach[®]
- Revenue up 12.6% to \$3.2 million¹
- Commercial readiness for Australian Detach[®] product launch
 - Progressing a parallel strategy to be independently ready for an Australian Detach[®] product launch
 - Extensive market research project completed, launch strategy underway
 - Design of a proprietary dosing device for optimal Detach[®] delivery



Key FY17 Achievements Cont.

- ~\$840,000 R&D tax refund received for 2015-16 activities
- Research facility established in Melbourne and R&D team expanded
- \$315,000 Science and Industry Endowment Fund's (SIEF) STEM+ Business Fellowship Program Grant received to develop the human and veterinary product pipeline
- \$100,000 QLD Government Ignite Ideas Grant Funding to support commercial roll out of Detach[®]
- Progression of 2 key patent applications
 - Detach[®] patent proceeded to National Phase
 - Bromelain fraction patent proceeded to International Phase



Key FY17 Achievements Cont.

- Target Animal Safety Study completed – confirming Detach[®] is safe
- “No Maximum Residue Limit” status granted by the European Medicines Authority (EMA) for bromelain, the active pharmaceutical ingredient in Detach[®]
- Positive regulatory meetings with USA, EU and Canadian authorities
- Renewal of Anatará’s SME status with the EMA
- Renewal of Anatará’s fee-waiver status with the FDA




Need to combat antimicrobial resistance (AMR)

“We have reached an historic turning point. We must not let this moment pass. The cost of inaction would be unbearable.”

Dr Tedros, Director-General, World Health Organisation (WHO) 2017 UNGA

AMR driven by the overuse of antimicrobials

- **70%** of bacteria globally has developed some level of resistance to antibiotics¹
- **10 million**: the number of people who will die every year due to AMR by 2050²
- **\$100 trillion**: the estimated total GDP that will be lost globally by 2050 if AMR isn't tackled²



Detach[®] - Commercial Readiness

- Commercially validated, supported by demand
- APVMA review of this application is currently underway and has met all prospective review timelines
- Anticipated Australian product launch in 2018
- Manufacturing tested at commercial scale
- Market position of Detach[®] is supported by industry, government, retailer and consumer demand
- Focus now is on finalising market launch plan
 - Intelligence gathering, market understanding and parallel (alternative) launch plans being finalised
- Design of a proprietary dosing device for optimal product delivery on farms



Zoetis at a glance



- Zoetis (zō-EH-tis) are the **#1 global animal health company**
- **60+ years** of experience in animal health
- **120+ countries** in which Zoetis products are sold
- **~\$5 billion** annual revenue
 - 65% revenue from farm animal products
 - 34% revenue from companion animal products
- **10,000 staff** including 3600+ field force
- **8 animal species** – cattle, swine, poultry, sheep, fish, dogs, cats and horses
- **5 product categories** – anti-infectives, vaccines, medicinal feed additives, parasiticides & other pharmaceutical products



What Next?

Detach[®] - A Pipeline in a Product

Potential product extensions for the active components of Detach[®]

Partnering and Development Opportunities for:

- Human gastrointestinal conditions (diarrhoea; inflammatory bowel disease; irritable bowel syndrome)



Anatara technology – for humans

Anti-secretory and anti-inflammatory action of Detach[®] actives may be used to control diarrhoea in gastrointestinal conditions, such as:

- Inflammatory bowel disease
- Irritable bowel syndrome and
- Traveller's diarrhoea

Disorders of significant unmet need not addressed by current products

Major therapeutic area with wide consumer knowledge

- Google *“gut health books”*



Major Market Opportunity for Anantara Human GI disorders/disease

- Substantial patient population with unmet need despite availability of numerous therapies
- GI disorders are highly symptomatic and a common reason why people seek medical treatment
- GI disorders are associated with significant quality-of-life issues because of pain and **abnormal bowel habits**
- Need for effective therapies that are safe enough for chronic use
- Major Pharma have significant interest in GI therapeutic area
- A fast growing opportunity exists for compounds that can be administered orally, with a similar or better effect, ***and with a low side effect profile*** when compared with existing IBS and IBD treatments



Detach[®] for Humans – Development Plans

Goal

- To develop proprietary bromelain-based medical foods and/or dietary supplements for the management of diarrhoea associated with gastrointestinal disorders

Strategy

- Leverage off the strong preclinical data obtained on Detach[®]
- Undertake proof of concept studies in relevant models
- Conduct human clinical studies to support efficacy claims



Thank you

Anatara's naturally derived products will offer safe and effective non antibiotic solutions for gastrointestinal diseases. The Company is uniquely positioned to fulfil a currently unmet need in the global health market.

Dr Mel Bridges, CEO & Chairman, Anatara Lifesciences

Dr Mel Bridges, CEO, Chairman & Co-founder
mbridges@anatara.com
+61 413 051 600

www.anataralifesciences.com
 @AnataraANR

